rewirebio.iobenchmarks
Evidence claim

Relevance of ctdnajam-20261010-protocol-ccga1-validation-sens-98spec to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?"

Use case
Select a plasma ctDNA fragmentomics detection workflow
Assessed by
CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity
Relevance
Proxy evidence
Endpoint
Sensitivity (95% CI, TP/total) at 98% specificity on the validation set, after unblinding for the fragment classifiers, for the fragment endpoint (18%) and fragment length (29%) classifiers from 30x cfDNA WGS, against whole-genome methylation (34%) and other classifiers on the same participants

A held-out same-sample comparison of fragmentomic classifiers with other cfDNA features at a fixed false-positive rate. Proxy evidence for the same reasons as the training result: no tumour-fraction strata, post hoc development of the fragment classifiers, post hoc threshold.

9 reviewed evaluations

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

21 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Citation locations
1 values
  • source id
    ctdnajam-20261010-source-jamshidi2022
    locator
    Table 3, validation columns and footnotes
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.citation_locators

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Comparison group
jamshidi2022-ccga1-detection
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.comparison_group

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Comparison title
CCGA substudy 1: cfDNA classifiers on the same participants at a post hoc 98% specificity
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.comparison_title

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Constraints
3 values
  • Inspect every linked evaluation's source locator and preserved limitations before citing a result.
  • Do not combine this mapping's evaluations with any other protocol's results; cohorts, assays and thresholds differ.
  • The 98% specificity threshold was set post hoc within each set and is not a locked screening threshold.
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.constraints

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Endpoint
Sensitivity (95% CI, TP/total) at 98% specificity on the validation set, after unblinding for the fragment classifiers, for the fragment endpoint (18%) and fragment length (29%) classifiers from 30x cfDNA WGS, against whole-genome methylation (34%) and other classifiers on the same participants
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.endpoint

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Excluded evaluations
1 values
  • id
    ctdnajam-20261010-eval-validation-pan-feature
    reason
    Pan-feature classifier over all nine cfDNA classifier scores, including methylation and mutation scores; not a fragmentomics workflow, and developed after validation blinding was lifted. Excluded at independent review 2026-10-10.
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.excluded_evaluations

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Claimed field
links:assessed_by:ctdnajam-20261010-protocol-ccga1-validation-sens-98spec
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.field

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Headline metric
sensitivity-at-98-percent-specificity
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.headline_metric

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Limitations
9 values
  • Developer study: GRAIL designed the assays and classifiers, ran every arm, and reports the comparison.
  • The 98% specificity threshold was set post hoc within each set, including the validation set, so it is not a threshold locked before validation.
  • Case-control enrolment of clinically diagnosed cancers and matched non-cancer participants, not an intended-use screening population.
  • Prototype assays; the targeted methylation test developed afterwards is a different assay and is not scored here.
  • The fragment endpoints, fragment lengths, allelic imbalance and pan-feature classifiers were developed after validation blinding was lifted; the other classifiers were blinded.
  • Table 3 scores 833 training and 464 validation cancers against 854 and 485 analysable cancers in Table 1. STAR Methods restrict detection to solid cancers, and Table 1 lists 11 plasma cell neoplasms and 10 leukaemias in training and 8 and 13 in validation, which is 21 in each set; lymphomas stay in.
  • Specificity was 97.9% (548/560) in training and 97.8% (354/362) in validation for every cfDNA classifier, slightly below the 98% target.
  • No sensitivity within tumour-fraction strata is printed; per-classifier clinical limits of detection by cTAF are in figures only.
  • The fragment endpoint, fragment length and allelic imbalance classifiers were developed after validation blinding was lifted, so their validation values are not a blinded validation, even though the source calls the cohort held-out; the copy-number, mutation, methylation and clinical rows were analysed double-blinded.
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.limitations

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Pinned records
21 values
  • record id
    ctdnajam-20261010-eval-validation-allelic-imbalance
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    e5d8018df9aaca18a820384ef368fe46dba2b56c0ec3538c30c08bd88ade00ed
  • record id
    ctdnajam-20261010-eval-validation-clinical-data
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    9acccfeb5c5d122fa37e9182d0b0463c58157aba3884ebab1f449c412950b2cd
  • record id
    ctdnajam-20261010-eval-validation-fragment-endpoints
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    88a7d9c9f940db10274d358871d014585a828b69abb1d06340561ddacb109444
  • record id
    ctdnajam-20261010-eval-validation-fragment-lengths
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    71266e2f973c35ed8bb9c49ae3f8361a7ab9e2eac8fdb2f8a5f9b31f436b4ab7
  • record id
    ctdnajam-20261010-eval-validation-scna
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    92a1c5a205452c2dd95c5bb2c4f13e513014eb41176676e827935b1371d341db
  • record id
    ctdnajam-20261010-eval-validation-scna-wbc
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    2e81cf24df947c08bba5062a168088cb95f4a7e2fd73579d5267434b6630878e
  • record id
    ctdnajam-20261010-eval-validation-snv
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    f1135018a2fb35072b121640005f02fdad5bb113e94010f3b7cc6de257e86411
  • record id
    ctdnajam-20261010-eval-validation-snv-wbc
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    8038775c7848b78bc6e165728024248fc3c34edcc4622c7897a10af8f75fcbf0
  • record id
    ctdnajam-20261010-eval-validation-wg-methylation
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    67308b83c8607fd2fb7740bd85b88ced6d2fd3e8141d03ef776560b8016fbe35
  • record id
    ctdnajam-20261010-protocol-ccga1-validation-sens-98spec
    fields
    • status
    • name
    • description
    • facets
    • source_ids
    • links
    • attributes
    sha256
    20ffe90ea58ab3d334e77d8fa1d0ec0cde9231d4d0bc77a3bee167f12e7eb756
  • record id
    ctdnajam-20261010-result-validation-allelic-imbalance-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    8693e0e5ce53dd0b61548d94811007611436bcf9fcc4b52a4d79b075f1195d50
  • record id
    ctdnajam-20261010-result-validation-clinical-data-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    f0b6b98aead2b135e70bec77363a72a7a8297c7c5da2e49f1328d93898bfbeae
  • record id
    ctdnajam-20261010-result-validation-fragment-endpoints-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    6b25421dd48804a83e9dc14a1ff167839d4c1f0d8a7f42f337312cd2b5e23707
  • record id
    ctdnajam-20261010-result-validation-fragment-lengths-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    bc3c4a6cc76af09977fa1bb4a3197d10f97baa1957b275a039fe3771d77aeea3
  • record id
    ctdnajam-20261010-result-validation-scna-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    b8f61d415953846234e1dc5c9f7759b7871bec0331aece765435dc4207ffea35
  • record id
    ctdnajam-20261010-result-validation-scna-wbc-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    ca57272ec3d0b2aa050284a89149d13792db4c32418fa441200187f071be8e5b
  • record id
    ctdnajam-20261010-result-validation-snv-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    e17f4878015a270104d99f8da54cc1a3fb296e8791a99b200a9a390cbc4bb543
  • record id
    ctdnajam-20261010-result-validation-snv-wbc-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    9167f27958cef583fcdfcf8921ce9f7aa3d0c3103f2c04084da872972de9f9ed
  • record id
    ctdnajam-20261010-result-validation-wg-methylation-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    c0509264f208ac500b83daf15c002594045eb2995a6a182fcf6b7d82c741e4e2
  • record id
    ctdnajam-20261010-source-jamshidi2022
    fields
    • status
    • attributes.artifact_sha256
    sha256
    49c49ed0c10c6121644dee3068618d9f5a06bbc63f5979bc8417acd9c1c0e56e
  • record id
    use-case-plasma-ctdna-fragmentomics
    fields
    • status
    • name
    • description
    • facets
    • attributes.question
    • attributes.decision
    • attributes.inputs
    • attributes.output
    • attributes.exclusions
    • attributes.setting
    • attributes.clinical_scope
    • attributes.intended_users
    sha256
    01d27c2ce64a391055bddc6dec9d5db208df9bee3d5e679045dd3f4f04a0ca08
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.pins

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and extraction receipts

Stable ID: use-case-mapping-ctdna-jamshidi-20261010-frag-validation

field
links:assessed_by:ctdnajam-20261010-protocol-ccga1-validation-sens-98spec
value
ctdnajam-20261010-protocol-ccga1-validation-sens-98spec
relevance
proxy
endpoint
Sensitivity (95% CI, TP/total) at 98% specificity on the validation set, after unblinding for the fragment classifiers, for the fragment endpoint (18%) and fragment length (29%) classifiers from 30x cfDNA WGS, against whole-genome methylation (34%) and other classifiers on the same participants
rationale
A same-sample comparison on the validation set of fragmentomic classifiers with other cfDNA features at a fixed false-positive rate. Proxy evidence for the same reasons as the training result: no tumour-fraction strata, post hoc development of the fragment classifiers, post hoc threshold. The CCGA samples are not public and none of the cohorts behind this use case's existing judgements comes from CCGA, so the samples do not overlap.
constraints
Inspect every linked evaluation's source locator and preserved limitations before citing a result.; Do not combine this mapping's evaluations with any other protocol's results; cohorts, assays and thresholds differ.; The 98% specificity threshold was set post hoc within each set and is not a locked screening threshold.
limitations
Developer study: GRAIL designed the assays and classifiers, ran every arm, and reports the comparison.; The 98% specificity threshold was set post hoc within each set, including the validation set, so it is not a threshold locked before validation.; Case-control enrolment of clinically diagnosed cancers and matched non-cancer participants, not an intended-use screening population.; Prototype assays; the targeted methylation test developed afterwards is a different assay and is not scored here.; The fragment endpoints, fragment lengths, allelic imbalance and pan-feature classifiers were developed after validation blinding was lifted; the other classifiers were blinded.; Table 3 scores 833 training and 464 validation cancers against 854 and 485 analysable cancers in Table 1. STAR Methods restrict detection to solid cancers, and Table 1 lists 11 plasma cell neoplasms and 10 leukaemias in training and 8 and 13 in validation, which is 21 in each set; lymphomas stay in.; Specificity was 97.9% (548/560) in training and 97.8% (354/362) in validation for every cfDNA classifier, slightly below the 98% target.; No sensitivity within tumour-fraction strata is printed; per-classifier clinical limits of detection by cTAF are in figures only.; The fragment endpoint, fragment length and allelic imbalance classifiers were developed after validation blinding was lifted, so their validation values are not a blinded validation, even though the source calls the cohort held-out; the copy-number, mutation, methylation and clinical rows were analysed double-blinded.
citation locators
source id: ctdnajam-20261010-source-jamshidi2022; locator: Table 3, validation columns and footnotes
source locator
ctdnajam-20261010-source-jamshidi2022: Table 3, validation columns and footnotes
revision
1
reason
Add the CCGA substudy 1 same-sample comparison of cfDNA classifiers (Jamshidi et al. 2022), retrieved 2026-10-10.
comparison group
jamshidi2022-ccga1-detection
comparison title
CCGA substudy 1: cfDNA classifiers on the same participants at a post hoc 98% specificity
headline metric
sensitivity-at-98-percent-specificity
stratum label
Validation set (fragment classifiers developed after unblinding)
stratum order
2
excluded evaluations
id: ctdnajam-20261010-eval-validation-pan-feature; reason: Pan-feature classifier over all nine cfDNA classifier scores, including methylation and mutation scores; not a fragmentomics workflow, and developed after validation blinding was lifted. Excluded at independent review 2026-10-10.
reviewed evaluations
ctdnajam-20261010-eval-validation-allelic-imbalance; ctdnajam-20261010-eval-validation-clinical-data; ctdnajam-20261010-eval-validation-fragment-endpoints; ctdnajam-20261010-eval-validation-fragment-lengths; ctdnajam-20261010-eval-validation-scna; ctdnajam-20261010-eval-validation-scna-wbc; ctdnajam-20261010-eval-validation-snv; ctdnajam-20261010-eval-validation-snv-wbc; ctdnajam-20261010-eval-validation-wg-methylation
review
method: automated-source-review; reviewer: claude; reviewer note: Separate Claude review agent, independent of the extractor; no human review claimed; reviewed at: 2026-10-10T09:00:00Z; note: Independent review of endpoint fit, relevance grade, limitations, exclusions and grouping against the use case and the article; every value of the listed evaluations was checked against Table 3 or the Results text, with percentages and Clopper-Pearson intervals recomputed. Developer study; no execution, reproduction, human scientific review or clinical validation.
pins
record id: ctdnajam-20261010-eval-validation-allelic-imbalance; fields: status; links; attributes.origin; attributes.comparison; sha256: e5d8018df9aaca18a820384ef368fe46dba2b56c0ec3538c30c08bd88ade00ed; record id: ctdnajam-20261010-eval-validation-clinical-data; fields: status; links; attributes.origin; attributes.comparison; sha256: 9acccfeb5c5d122fa37e9182d0b0463c58157aba3884ebab1f449c412950b2cd; record id: ctdnajam-20261010-eval-validation-fragment-endpoints; fields: status; links; attributes.origin; attributes.comparison; sha256: 88a7d9c9f940db10274d358871d014585a828b69abb1d06340561ddacb109444; record id: ctdnajam-20261010-eval-validation-fragment-lengths; fields: status; links; attributes.origin; attributes.comparison; sha256: 71266e2f973c35ed8bb9c49ae3f8361a7ab9e2eac8fdb2f8a5f9b31f436b4ab7; record id: ctdnajam-20261010-eval-validation-scna; fields: status; links; attributes.origin; attributes.comparison; sha256: 92a1c5a205452c2dd95c5bb2c4f13e513014eb41176676e827935b1371d341db; record id: ctdnajam-20261010-eval-validation-scna-wbc; fields: status; links; attributes.origin; attributes.comparison; sha256: 2e81cf24df947c08bba5062a168088cb95f4a7e2fd73579d5267434b6630878e; record id: ctdnajam-20261010-eval-validation-snv; fields: status; links; attributes.origin; attributes.comparison; sha256: f1135018a2fb35072b121640005f02fdad5bb113e94010f3b7cc6de257e86411; record id: ctdnajam-20261010-eval-validation-snv-wbc; fields: status; links; attributes.origin; attributes.comparison; sha256: 8038775c7848b78bc6e165728024248fc3c34edcc4622c7897a10af8f75fcbf0; record id: ctdnajam-20261010-eval-validation-wg-methylation; fields: status; links; attributes.origin; attributes.comparison; sha256: 67308b83c8607fd2fb7740bd85b88ced6d2fd3e8141d03ef776560b8016fbe35; record id: ctdnajam-20261010-protocol-ccga1-validation-sens-98spec; fields: status; name; description; facets; source_ids; links; attributes; sha256: 20ffe90ea58ab3d334e77d8fa1d0ec0cde9231d4d0bc77a3bee167f12e7eb756; record id: ctdnajam-20261010-result-validation-allelic-imbalance-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 8693e0e5ce53dd0b61548d94811007611436bcf9fcc4b52a4d79b075f1195d50; record id: ctdnajam-20261010-result-validation-clinical-data-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: f0b6b98aead2b135e70bec77363a72a7a8297c7c5da2e49f1328d93898bfbeae; record id: ctdnajam-20261010-result-validation-fragment-endpoints-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 6b25421dd48804a83e9dc14a1ff167839d4c1f0d8a7f42f337312cd2b5e23707; record id: ctdnajam-20261010-result-validation-fragment-lengths-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: bc3c4a6cc76af09977fa1bb4a3197d10f97baa1957b275a039fe3771d77aeea3; record id: ctdnajam-20261010-result-validation-scna-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: b8f61d415953846234e1dc5c9f7759b7871bec0331aece765435dc4207ffea35; record id: ctdnajam-20261010-result-validation-scna-wbc-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: ca57272ec3d0b2aa050284a89149d13792db4c32418fa441200187f071be8e5b; record id: ctdnajam-20261010-result-validation-snv-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: e17f4878015a270104d99f8da54cc1a3fb296e8791a99b200a9a390cbc4bb543; record id: ctdnajam-20261010-result-validation-snv-wbc-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 9167f27958cef583fcdfcf8921ce9f7aa3d0c3103f2c04084da872972de9f9ed; record id: ctdnajam-20261010-result-validation-wg-methylation-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: c0509264f208ac500b83daf15c002594045eb2995a6a182fcf6b7d82c741e4e2; record id: ctdnajam-20261010-source-jamshidi2022; fields: status; attributes.artifact_sha256; sha256: 49c49ed0c10c6121644dee3068618d9f5a06bbc63f5979bc8417acd9c1c0e56e; record id: use-case-plasma-ctdna-fragmentomics; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: 01d27c2ce64a391055bddc6dec9d5db208df9bee3d5e679045dd3f4f04a0ca08
Related records

Suggest a correction